Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non–Small-Cell Lung Cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conjugate, in patients with HER2-mutant NSCLC have not been investigated extensively.

Related collections

Author and article information

Contributors

Lyudmila Bazhenova: (View ORCID Profile)

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date (Electronic): September 18 2021

Affiliations

[1 ]From Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York (B.T.L.); the Netherlands Cancer Institute, Amsterdam (E.F.S); the National Cancer Center Hospital, Tokyo (Y.G.), Kindai University Hospital, Osaka (K.N.), and the National Cancer Center East, Kashiwa (H.U.) — all in Japan; Centre Hospitalier Universitaire, Toulouse (J.M.), Centre Léon Bérard, Lyon (M.P.), and the Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif (D.P.) — all in France; Karmanos...

Article

DOI: 10.1056/NEJMoa2112431

SO-VID: e504bb74-cf59-417c-92aa-208eaa7b6f0c

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 256

See all cited by

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Read this article at